FUDANZHANGJIANG Places RMB150.00 Million in 89-Day Principal-Protected Structured Deposit with Bank of China

Bulletin Express
04/02

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd. (FUDANZHANGJIANG) has signed a structured deposit product agreement with Bank of China, committing RMB150.00 million of temporarily idle A-share proceeds to a low-risk, principal-guaranteed instrument that offers floating returns.

Key transaction terms • Product: “RMB Structured Deposit of Bank of China” (principal-guaranteed, floating return). • Tenor: 89 days, effective 2 April 2026. • Expected annualised return: 0.35%–1.57%, determined by the performance of the EUR/USD central parity spot rate on Bloomberg (BFIX). – If the rate during 3 April–25 June 2026 is ever not lower than the observation level (benchmark +0.0515), the return is 0.35%. – If consistently below that level, the return rises to 1.57%. • Early termination: Not available to the Company; Bank of China retains termination rights under force majeure or public-interest considerations. • Risk rating: Low, per Bank of China assessment.

Regulatory position Applicable percentage ratios under Hong Kong Listing Rule 14.07 exceed 5% but are below 25%, classifying the deal as a disclosable transaction. Hence, it requires public reporting and announcement but no shareholder approval.

Strategic rationale Deploying idle IPO proceeds into a short-tenor, capital-protected instrument is intended to enhance overall returns while safeguarding liquidity—consistent with the Group’s treasury objectives. The board, including independent non-executive directors, deems the terms fair, reasonable and aligned with shareholder interests.

Counterparties • FUDANZHANGJIANG: PRC-based biopharmaceutical company listed in Hong Kong and on Shanghai’s STAR Market. • Bank of China: PRC state-owned commercial bank listed in Shanghai and Hong Kong; confirmed as an independent third party to the Company.

Directors as of 2 April 2026: Zhao Da Jun (Chairman & Executive Director), Xue Yan (Executive Director), Shen Bo and Yu Xiao Yang (Non-executive Directors), Wang Hong Guang, Lam Siu Wing, Xu Pei Long (Independent Non-executive Directors), and Qu Ya Nan (Employee Director).

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10